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DOI 10.1016/j.ccr.2011.12.024SUMMARYThe PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents
an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian
cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant.
This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs
that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of
several upregulated proteins, including Bcl-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibi-
tion. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached
cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of
this resistance mechanism through rational design of drug combinations could significantly enhance
PI3K-targeted drug efficacy.INTRODUCTION
The most prevalent forms of cancer are of epithelial origin.
Normal epithelial cells form well-organized polarized cell layers
under the influence of extracellular matrix (ECM), and attach-
ment to ECM is required for the control of normal epithelial cell
proliferation, differentiation, and survival (Debnath and Brugge,
2005). However, during cancer progression, the normal epithelial
organization is disrupted and malignant cells proliferate and
survive outside their normal niches (Chiarugi and Giannoni,
2008). This process is not well recapitulated in two-dimensional
(2D) cell cultures and may explain, in part, the failure of many
therapeutic approaches in clinical trials. Thus, there is a need
and opportunity to explore mechanisms of drug response and
resistance under culture conditions that more closely mimic
the in vivo environment.Significance
To fulfill the promise of PI3K/mTOR-pathway inhibition in ca
develop therapies to overcome it. Here, we show that resis
associated with upregulation of an evolutionarily well-conserv
translation of IRES-containing mRNAs previously associated w
to upregulation of prosurvival proteins, and inhibition of this
breast and ovarian cancer cells and ovarian cancer xenografts
of effective drug combinations through the use of three-dime
proteomics approaches and identify drug combinations for fu
CThree-dimensional (3D) cell culture models have been widely
utilized in epithelial cancer research to probe mechanisms
involved in tumor initiation and progression (Debnath and
Brugge, 2005; Weigelt and Bissell, 2008; Yamada and Cukier-
man, 2007). Nontransformed epithelial cells cultured in reconsti-
tuted basement membrane form hollow, growth-arrested,
polarized 3D structures that recapitulate many features of
epithelial cells in vivo. Survival of 3D spheroid structures is
dependent on attachment to ECM; inner cells, lacking ECM
attachment, undergo apoptosis, generating a hollow lumen
(Chiarugi and Giannoni, 2008; Debnath and Brugge, 2005).
However, cells that harbor alterations that inhibit apoptosis are
still compromised in their survival because of metabolic impair-
ment caused by ECM deprivation leading to decreased growth
factor signaling, mostly due to loss of nutrient uptake (Schafer
et al., 2009). These findings suggest that survival of tumor cellsncer, it is critical to identify mechanisms of resistance and
tance of matrix-attached cells to PI3K/mTOR-inhibitors is
ed program that resembles nutrient deprivation, leading to
ith cellular stress responses. This adaptive response leads
program abrogates resistance to PI3K/mTOR-inhibition in
. These studies provide a platform for rational development
nsional (3D) model systems together with high-throughput
rther analysis as cancer therapeutics.
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Adaptive Resistance to PI3K/mTOR Inhibitionoutside their natural matrix niches may require alterations that
allow them to escape both apoptosis and metabolic impairment.
Introduction of oncogenes into nontumorigenic cells in 3D can
result in the formation of solid, filled structures that resemble
tumor cells grown in 3D as well as the filled alveoli characteristic
of ductal carcinoma in situ, a noninvasive form of breast cancer
(Debnath and Brugge, 2005). Oncogenic alterations in the phos-
phatidylinositol 3-kinase (PI3K) pathway have been shown to
rescue matrix-deprived cells from apoptosis and metabolic
impairment and to cause filling of the luminal space in 3D
cultures (Debnath et al., 2003b; Isakoff et al., 2005).
In epithelial cancers, the signaling pathway most frequently
activated by genetic alterations is the PI3K pathway (Engelman,
2009; Samuels and Velculescu, 2004; Yuan and Cantley, 2008)
and can be activated by multiple mechanisms, including altered
DNA copy number and mutations of several of the components
of this pathway (Carpten et al., 2007; Gewinner et al., 2009; Li
et al., 1997; Samuels et al., 2004). Thus, this pathway presents
an attractive candidate for targeted therapeutics. In recent
years, many small molecule inhibitors targeting PI3K, AKT, and
the downstream effector mTOR, have been developed; several
are in clinical trials, and some (specifically, rapamycin analogs
targeting mTOR) have been approved for therapy (Baselga,
2011; Courtney et al., 2010). Most initial in vitro studies of these
inhibitors were performed in 2D monolayer cell cultures where it
is not feasible to examine the effects of the targeted therapeutics
on tumor-specific phenotypes such as loss of polarity and
survival without ECM attachment. However, in studies using
3D cultures, the effects of PI3K inhibition on tumor growth in vivo
correlated with effects on cell proliferation in 3D cultures more
accurately than in 2D cultures, suggesting that 3D cultures better
reflect drug sensitivity in vivo (Howes et al., 2007; Polo et al.,
2010). In addition, other studies have shown that signaling
pathway activation and drug responses in 3D cultures differ
substantially from 2D cultures (Kenny et al., 2007; Liu et al.,
2004; Weigelt et al., 2010), emphasizing the potential use of 3D
culture to ascertain underlying mechanisms of sensitivity and
resistance to targeted therapeutics as well as to predict effective
drug combinations.
Inhibition of PI3K/AKT can lead to upregulation and activation
of receptor tyrosine kinases (RTKs) through engagement of
several homeostatic feedback loops aimed at maintaining the
PI3K pathway in equilibrium. This includes a FOXO-dependent
pathway (Chandarlapaty et al., 2011; Garrett et al., 2011), as
well as compensatory activation of the MAPK pathway (Carra-
cedo et al., 2008; Engelman et al., 2008; Serra et al., 2011).
Inhibition of upstream components of the PI3K pathway has
been shown to lead to compensatory activation of HER3 (Ser-
gina et al., 2007). In addition, inhibition of mTORC1 by allosteric
inhibitors (e.g., rapamycin family) relieves a negative feedback
loop from S6K to IRS1, among others, leading to activation of
IGF1R, PI3K, and AKT (Cloughesy et al., 2008; Harrington
et al., 2004; O’Reilly et al., 2006). Activation of compensatory
pathways in response to PI3K/mTOR inhibition may limit the
efficacy of drugs targeting this pathway, leading to paradoxical
responses and possibly contributing to emergence of drug-
resistant clones.
In this report, we examined the response of ovarian and breast
tumor cells in 3D spheroid cultures to PI3K and mTOR inhibitors228 Cancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc.in order to monitor drug-induced phenotypic changes that could
not be assayed in standard 2D cultures.
RESULTS
Dichotomous Response to PI3K Pathway Inhibition
in Tumor Spheroids
To examine how ovarian cancer cells cultured as 3D spheroids in
reconstituted basement membrane (Matrigel) respond to inhibi-
tion of the PI3K/mTOR pathway, we treated several ovarian
cancer cell lines with BEZ235, a dual-specificity PI3K/mTOR
inhibitor (Maira et al., 2008). In 3D culture, OV2008, SKOV3,
and OVCA432 cell lines form spheroid structures with a constitu-
tive low level of proliferation (marked by Ki67 staining) localized
predominantly in the outer matrix-attached cell layer (Figure 1A).
A small number of apoptotic cells, marked by cleaved caspase-3
staining, were detected almost exclusively in the middle of the
structures. Treatment of 6-day-old spheroids with BEZ235
induced a striking dichotomy in the induction of apoptosis
between outer and inner cells, with apoptosis being exclusively
localized in the inner region of the spheroids (Figure 1B; Fig-
ure S1A available online). MCAS cells, which form structures
with hollow lumens, were largely resistant to apoptosis. Although
apoptosis was restricted to inner cells, BEZ235 treatment sup-
pressed proliferation throughout the structures (data not shown).
OV2008 cells were treated cells with a wider selection of PI3K or
mTOR inhibitors (Rapamycin, LY294002, GDC0941, and PIK-90)
to determine the generality of this response. All inhibitors
induced a similar dichotomy in apoptosis between the drug-
resistant matrix-attached outer cells and the inner matrix-
deprived cells (Figure S1B).
Multiple Signaling Pathways Are Upregulated
by PI3K/mTOR Inhibition
Outer 3D tumor spheroid cells could be intrinsically drug resis-
tant, or drug treatment could induce resistance. To examine
these possibilities, we performed reverse phase protein array
(RPPA) analysis of 120 proteins and phosphoproteins repre-
senting many major signaling pathways (Figure 2A). As ex-
pected, BEZ235 treatment decreased phosphorylation of
proteins downstream of PI3K and mTOR (p-FOXO3a, p-4E-
BP1) and reduced cell proliferation markers (PCNA, cyclinB1,
cyclinE1) (Figure 2A). However, BEZ235 also induced upregula-
tion and/or activation of multiple prosurvival proteins (Figure 2A),
including several RTKs (EGFR, HER2, c-Kit, and IGF1R), cyto-
plasmic kinases (p-p90RSK, p-SrcY), antiapoptotic proteins
(Bcl-2, XIAP1), and transcription factors (p-STAT3, p-STAT6,
p-c-Jun, p-SMAD3). This response was not unique to 3D cell
cultures, as 2D cultures treated with BEZ235 displayed similar
responses, with multiple survival pathways being activated by
BEZ235 (Figure 2A). A comparable response was also observed
in BEZ235-treated MCAS spheroids and monolayer cultures
(Figures S2A and S2B), with upregulation of Bcl-2, IGF1Rb,
p-STAT3, p-STAT6, p-c-Jun, p-SMAD3, p-p90RSK, EGFR,
and p-HER2; however, Bcl-xL and p-Erk were also upregulated
in MCAS cells.
RPPA results were validated by western blot for Bcl-2,
p-IGF1Rb, c-Jun, p-p90RSK, p-EGFR, p-S6, and p-4E-BP1
(Figures 2B; Figure S2B). While detectable changes in total
Figure 1. Ovarian Cancer Cell Lines Form Acinilike Structures in
Reconstituted Basement Membrane and Matrix-Attached Cells
Show Resistance to BEZ235-Induced Apoptosis
(A) Ovarian cancer cell lines (PIK3CA mutations indicated in parentheses)
MCAS (H1047R), SKOV3 (H1047R), OVCA432 (unknown) and OV2008 (E545K)
were cultured in Matrigel for 6 days and stained for Ki67 (red) or cleaved
caspase-3 (red) and counterstained with DAPI (blue). (Mutation information
was provided by S. Jones and V. Velculescu, personal communication.) One
representative phase or confocal section is shown.
(B) OV2008, MCAS, and OVCA432 cells were cultured in Matrigel for 4 days
and 1 mM BEZ235 was added for 48 hr before the cells were fixed, stained for
cleaved caspase-3 (red) and DAPI (blue) and imaged by confocal microscopy.
Confocal scale bar, 50 mm; phase contrast scale bar, 200 mm. See also
Figure S1.
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detected up- or downregulation, respectively, upon BEZ235
treatment by western blotting. Total protein levels of 4E-BP1
inversely correlated with those of p-4E-BP1 as previously re-
ported (Yamaguchi et al., 2008). Furthermore, we confirmed
that p-Erk was unaffected by BEZ235 treatment (Figure 2B).
To examine whether the proteins induced by BEZ235 were
specifically induced in matrix-attached outer cells, we per-
formed immunofluorescence analysis of Bcl-2 and Bcl-xL inCBEZ235-treated OV2008 and MCAS cells. Indeed, upregulation
of Bcl-2 and Bcl-xL was strongly enriched in outer, ECM-
attached cells (Figure S2C). As ECM contact activates integrins,
we addressed whether blocking integrin signaling could inhibit
the adaptive response of the matrix-attached outer cells. Down-
regulation of b1-integrin, b4-integrin, FAK, or ILK alone did not
abrogate Bcl-2 or IGF1R upregulation; however, inhibition of
several integrin-pathway components in parallel, prevented up-
regulation of these proteins (Figure S2H). These results suggest
that multiple integrins may contribute to the adaptive program;
this possibility was supported by the evidence that additional
integrins are induced at the transcriptional level by BEZ235 treat-
ment (Figure S2I).
Inhibition of Bcl-2, IGF1R, or EGFR in Combination with
BEZ235 Abrogates Matrix Protection
As BEZ235 treatment induced upregulation of several cell
survival pathways, we assessed whether these pathways are
critical for the resistance of matrix-attached cells. Given the crit-
ical role of Bcl-2 family members in regulation of cell survival
(Walensky, 2006), we first examined the effects of inhibiting
Bcl-2 family proteins in combination with BEZ235. Treatment
with the Bcl-2 family inhibitor ABT-737, which targets Bcl-2,
Bcl-xL, and Bcl-w (Oltersdorf et al., 2005), induced apoptosis
of inner spheroid cells but did not affect survival of outer cells
(Figure 2C). However, combined treatment with ABT-737 and
BEZ235 induced massive disintegration of the spheroids. Immu-
nostaining for cleaved caspase-3 confirmed extensive apoptosis
throughout the entire spheroid structure (Figure 2C). Similar
effects were observed using the structurally distinct Bcl-2 inhib-
itor, HA-14.1 (Figure S2D). Analysis of four additional ovarian
cancer cell lines revealed similar synthetic lethality of ABT-737
and BEZ235 (Figure S2E).
We also examined whether the BEZ235-induced RTKs EGFR
and IGF1R are essential for survival of BEZ235-treated cells.
BEZ235 treatment together with EGFR inhibitors PD168393 or
Gefitinib caused marked cell death (Figure S2F). In addition,
downregulation of IGF1R with shRNAs caused death of ECM-
attached cells treated with BEZ235 (Figure S2G). To address
whether inhibition of other antiapoptotic signaling proteins that
were not induced in the ECM-attached cells by BEZ235 would
synergize with BEZ235, we incubated BEZ235-treated cells
with inhibitors of MEK, PKC, PKA, Jak, or IKK. Inhibition of these
proteins in combination with BEZ235 did not enhance death of
outer, ECM-attached cells (Figure S2D; data not shown). These
results imply that BEZ235-treatment selectively induces expres-
sion of several prosurvival proteins in ECM-attached cells and
indicate that some of these induced proteins, such as Bcl-2,
EGFR, and IGF-1R, are required for cancer cell survival. Our
studies also validate RPPA as an efficient tool in identifying
drug resistance proteins and pathways.
Many Induced Proteins Are Upregulated at the mRNA
Level through FOXO-Dependent Transcription
To address whether BEZ235-induced protein upregulation
reflects changes in mRNA expression, we performed mRNA mi-
croarray analyses on drug-treated OV2008 and MCAS cells
cultured in 3D. Several genes, such as IGF1R, EGFR, BCL2,
IRS1, and SMAD3, displayed increased mRNA expression,ancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc. 229
Figure 2. RPPA Reveals Multiple Proteins Upregulated in BEZ235-Treated Cells
(A) OV2008 and SKOV3 cells were cultured in Matrigel (3D) or monolayer (2D) and treated with BEZ235 or DMSO, and the protein lysates were analyzed by RPPA
(red, increased signal; and green, decreased signal, upon BEZ235 treatment). Samples are normalized against DMSO-treated controls. Proteins with significant
differences (p < 0.05, Student’s t test) between BEZ235- and DMSO-treated OV2008 cells in an experiment performed in triplicate are shown for all experiments.
(B) Several of the up- and downregulated proteins from OV2008 RPPA were validated by western blot analysis.
(C) Bcl-2 inhibition abrogates outer cell resistance to PI3K/mTOR inhibition. MCAS and OV2008 cell lines were cultured in 3D and treated with DMSO, BEZ235, or
ABT737 alone or in combination for 48 hr. Cells were imaged by phase contrast, fixed, stained for cleaved caspase-3 (red), and imaged by phase contrast or
confocal microscopy. Confocal scale bar, 50 mm; phase contrast scale bar, 200 mm. See also Figure S2.
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part, changes in mRNA levels (Figure 3A).
Inhibition of PI3K prevents activation of AKT1/2/3, which
phosphorylates FOXO family transcription factors, preventing
their nuclear translocation (Brunet et al., 1999; Kops et al.,
1999). Because FOXO family members were recently demon-230 Cancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc.strated to induce transcription of several RTKs upon AKT inhibi-
tion (Chandarlapaty et al., 2011), we analyzed the mRNA expres-
sion array for FOXO targets. A significant enrichment of known
FOXO target genes were upregulated after BEZ235 treatment
(p = 0.00335, hypergeometric probability distribution), including
CDKN1B (p27Kip1), TSC1, IRS2, and FOXO1/3 (Figure 3B).
Figure 3. Many of the Induced Proteins Are Upregulated at the
mRNA Level through FOXO-Dependent Transcription
(A) Heatmaps showing relative levels of mRNA of proteins that were upregu-
lated in the RPPA in OV2008 and MCAS cells; additional RTKs not present in
RPPA were also selected for analysis. mRNA values were normalized relative
to DMSO-treated cells. Red, upregulation in response to BEZ235 treatment;
and green, downregulation. Approximately 60% (12/20 for OV2008 and 11/19
for MCAS) of the proteins that are detectably upregulated in response to
BEZ235 in RPPAs and detected in the mRNA expression array show elevated
mRNA at either time point (p = 0.000385 for OV2008 and p = 0.041 for MCAS,
hypergeometric probability distribution). Proteins validated by western blots
are marked by an asterisk, and the direction of change is indicated in paren-
theses.
(B) Heatmap showing relative levels of mRNAs previously reported as FOXO
targets; of 117 reported FOXO targets, 31 are upregulated in at least two
conditions (p < .01), showing a significant enrichment (p = 0.00335, hyper-
geometric probability distribution).
(C) FOXO1 and FOXO3 were downregulated in OV2008 cells by siRNAs tar-
geting FOXO1 or FOXO3 (left) or transduction of a lentiviral vector encoding
shRNA for FOXO3, together with FOXO1 siRNAs (right). Lysates were probed
with antibodies to Bcl-2 and IGF1Rb to monitor upregulation upon 18-hr
BEZ235 treatment. The efficacy of the knockdowns was verified by western
blotting of FOXO1 and FOXO3.
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upregulated in BEZ235-treated cells (Figure 3B), suggesting that
FOXO could mediate transcription of some of the upregulated
proteins. Knockdown of either FOXO1 or FOXO3 reduced
IGF1Rb upregulation by BEZ235, whereas FOXO3 knockdown
reduced Bcl-2 as well; knockdown of both FOXO1 and FOXO3
inhibited upregulation of both Bcl-2 and IGF1Rb (Figure 3C).
Inhibition of the mTORC1 Target 4E-BP1 Correlates
with Upregulation of Bcl-2 and IGF1Rb
BEZ235 is a dual inhibitor of both PI3K and mTORC1/2. To
assesswhether inhibition of either PI3K or TORC1/2 is necessaryCand/or sufficient to induce Bcl-2 and synergize with ABT-737, we
examined several additional inhibitors of PI3K or mTOR:
GDC0941 (PI3K inhibitor at 250nM, PI3K, andmTOR at 1 mM), ra-
pamycin (allosteric mTOR inhibitor selective for mTORC1), and
Torin1 (mTORC1/2 catalytic inhibitor). The most cell death was
induced with ABT-737 in combination with either BEZ235,
Torin1, or GDC0941 at a concentration that also inhibits mTOR
(Figures 4A and 4B). Neither the PI3K-selective (250 nM
GDC0941) nor the mTORC1-specific (rapamycin) inhibitors
induced spheroid disintegration with ABT-737 (Figures 4A and
4B). Western blots demonstrated decreased p-4E-BP1 corre-
lated with Bcl-2 upregulation (Figure 4C). 4E-BP1 phosphoryla-
tion is relatively insensitive to rapamycin, and long-term
suppression of 4E-BP1 requires inhibition of mTOR catalytic
activity (Choo et al., 2008; Feldman et al., 2009; Thoreen et al.,
2009). We also noticed that inhibition of PI3K enhanced Bcl-2
upregulation, as 250 nM Torin1 significantly inhibited p-4E-
BP1, but did not induce Bcl-2 as efficiently as 1 mM Torin or
1 mMGDC0941, which inhibit both 4E-BP1 and AKT phosphory-
lation (Figure 4C). These findings demonstrate that reduced
4E-BP1 phosphorylation correlates with upregulation of Bcl-2,
but PI3K inhibition enhances this effect, likely through other
mechanisms such as FOXO activation.
Increased Cap-Independent Translation in Response
to mTOR Inhibition
mTORC1 activates cap-dependent translation by phosphory-
lating and inhibiting 4E-BP1. However, cell stress can suppress
cap-dependent translation through inhibition of mTOR. Under
these conditions, essential cell survival proteins (i.e., regulators
of cell cycle, development, apoptosis, and stress response) are
translated through a cap-independent mechanism (Holcik and
Sonenberg, 2005; Silvera et al., 2010). A switch to cap-indepen-
dent translation can also be achieved by direct inhibition of
mTORC1 or perturbation of 4E-BP1 (Braunstein et al., 2007;
Choo et al., 2008; Feldman et al., 2009; Hsieh et al., 2010;
Moerke et al., 2007; She et al., 2010; Thoreen et al., 2009).
mRNAs translated under these conditions have a highly struc-
tured 50-untranslated region (50-UTR), which often harbors an
IRES sequence and several upstream AUGs. It is interesting
that multiple proteins upregulated by BEZ235—including
Bcl-2, Bcl-xL, IGF1R, XIAP, c-Jun, and p53—can all be trans-
lated in a cap-independent manner under cellular stress. To
address whether cap-independent translation increases in
response to PI3K/mTOR inhibition, we used a bicistronic lucif-
erase reporter where Renilla luciferase is cap dependent and
firefly luciferase is regulated by the cap-independent cricket
paralysis virus IRES. Indeed, OV2008 and MCAS cells treated
with BEZ235 or Torin1 (Figure 5A), but not rapamycin or
250 nMGDC0941 (Figures S3A and S3B), upregulated cap-inde-
pendent translation, suggesting that an IRES translation is
induced by mTOR inhibitors.
We also utilized a BCL-2 IRES reporter that contains the BCL-2
50-UTR upstreamof firefly luciferase and is only translated by cap-
independent translation (Suo et al., 2010). A short unstructured
50-UTR reporter was used to monitor cap-dependent translation.
BEZ235 treatment caused an 38% increase in Bcl-2 IRES
translation with a concomitant 60% decrease in cap-dependent
reporter translation (Figure 5B). These results provide evidenceancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc. 231
Figure 4. Inhibition of 4E-BP1 Phosphorylation Correlates with the Upregulation of Bcl-2 and IGF1R and Disintegration of 3D Spheroids
(A) OV2008 cells were grown in 3D cultures for 4 days and treatedwith indicated inhibitors targeting PI3K and/ormTOR in combination with ABT-737 for 48 hr. The
cells were fixed, stained for cleaved caspase-3 (red) andDAPI (blue), and imagedwith phase and confocalmicroscopy. Confocal scale bar, 50 mm; phase contrast
scale bar, 200 mm.
(B) OV2008 cells were grown in 3D culture and treated with indicated drugs and quantitated for structural integrity after a 48-hr drug treatment as described in
Experimental Procedures. Representative images of scored structures (intact, semidisintegrated, and disintegrated) are shown in the lower panel; scale bar,
100 mm.
(C) Lysates were harvested from structures cultured in 3D and analyzed for Bcl-2 and IGF1Rb, p-4E-BP1T37/46, p-S6S240, and p-AKTS473 expression after the
indicated 48-hr drug treatments.
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tion while cap-dependent translation is inhibited.
Phosphorylation of the eukaryotic translation initiation factor 2
alpha (eIF2a), a component of the ternary translation initiation
complex, selectively suppresses cap-dependent translation in
response to cellular stress (Holcik and Sonenberg, 2005; Raven
and Koromilas, 2008; Silvera et al., 2010; Wek et al., 2006).
BEZ235 treatment increased eIF2a phosphorylation over time,
reaching a plateau at 24 hr in OV2008 and 48 hr in MCAS cells
(Figure 5C). Additionally, of 23 significantly upregulated proteins
after BEZ235 treatment identified by RPPA, 10 have putative or
validated IRES motifs. This represents a significant enrichment
(p = 0.0083), as only 3%–5% of all mRNAs have potential IRES
sequences (Johannes et al., 1999).232 Cancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc.Breast Tumor Cell Lines Also Display the Adaptive
Response to BEZ235 and Are Sensitive to Combined
PI3K/mTOR and Bcl-2 Inhibition
To test whether the BEZ235 response is induced in other epithe-
lial tumors, we performed RPPA on BEZ235-treated breast
cancer cell lines harboring mutations in PIK3CA or deletions in
PTEN. While there were variations in individual proteins that
were affected by treatment, the adaptive response was strikingly
similar, with PI3K/mTOR inhibition causing an induction of RTKs
(HER3, IGF1Rb, HER2, and EGFR), as well as Bcl-2 and Bcl-xL
(Figure 6A). We also detected an adaptive response to BEZ235
in nontransformedMCF10A cells, although themost strongly up-
regulated proteins varied relative to the breast tumor cell lines.
This likely reflects the dominance of the EGFR-ERK signaling
Figure 5. Cap-Independent Translation Increases
in Response to BEZ235 Treatment
(A) A dual luciferase reporter (Renilla luciferase expression
mediated by cap-dependent translation and firefly lucif-
erase expression by CrPV IRES) was used to monitor
cap-independent translation in OV2008 andMCAS cells in
response to BEZ235 or Torin1 treatment. The fold increase
in the ratio of the firefly/Renilla luciferase levels was
calculated as described in Experimental Procedures. *p <
0.05; **p < 0.01; ***p < 0.001.
(B) BCL-2 IRES translational activity was monitored by
a reporter containing the BCL2 IRES sequence upstream
of firefly luciferase. Cap-dependent translation was
monitored with a reporter containing a short unstructured
50UTR fused to firefly luciferase. Luciferase expression
from both reporters was normalized to luciferase mRNA
expression and shown as fold change compared to DMSO
control. Cartoon modified from Suo et al., 2010.
(C) Upregulation of eIF2a phosphorylation was monitored
in response to BEZ235 treatment over time in OV2008
and MCAS cells. Error bars shown as ± SEM. See also
Figure S3.
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Adaptive Resistance to PI3K/mTOR Inhibitionpathway in these cells (note upregulated p-EGFR, p-ERK,
p-BADS112, and downregulated Bim) (Figures 6A and 6D).
We also examined whether the breast tumor cell lines
would display enhanced cell death with combined inhibition of
PI3K/mTOR and Bcl-2 in 3D cultures. In contrast to the well-
organized ovarian cell lines, the breast cancer lines were less
organized, precluding detection of a clear dichotomy between
the outer and inner cell layers. However, as seen with ovarian
lines, inhibition of PI3K/mTOR or Bcl-2 family members alone
did not induce dramatic cell death, but combined treatment
caused significant structural disintegration and cell death in
MDA-MB-468 and HCC-1569 cells and, to a lesser extent, in
T-47D cells (Figure 6B). In contrast, the overall integrity of non-
transformed MCF-10A cell structures treated with both
BEZ235 and ABT-737 was not significantly affected, as cells in
contact with reconstituted matrix were resistant to apoptotic
effects of the combination (Figure 6C). Nontransformed, nonim-
mortalized human mammary epithelial cells (HMECs) also
showed no sensitivity to the dual treatment (Figure S4), indi-
cating that cancer cells are more sensitive to this treatment
than normal epithelial cells.
Mouse Xenografts and Primary Ovarian and Breast
Cancer Patient Samples Show Sensitivity to Dual
Inhibition of PI3K/mTOR and Bcl-2
To test the effectiveness of inhibiting PI3K/mTOR and/or the
Bcl-2 family in vivo, we performed xenograft studies withCancer Cell 21, 227subcutaneous injection of MCAS and OV2008
cells. Tumors were treated with the PI3K/
mTOR inhibitor GNE493 (Sutherlin et al., 2010)
and ABT-737 either alone or in combination
every 24 hr for 7–9 days. Vehicle and ABT-
737-treated MCAS tumors showed similar
growth rates, whereas GNE493 significantly
decreased tumor growth. Remarkably, com-
bined treatment caused marked inhibition of
tumor cell growth relative to GNE493 alone (Fig-ure 7A). Similar results were obtained with OV2008 xenograft
tumors (Figure 7A). Furthermore, hematoxylin and eosin (H&E)
staining of tumor sections revealed that combination treatment
induced increased cell death relative to single agents (Figure 7B).
Combination treatment caused weight loss during the 7-day
treatment (5% on average), and one mouse (of 23) showed
more significant weight loss (20%) and died on Day 7 of treat-
ment, indicating that the combination may have some toxicity.
Lysates from GNE493-treated MCAS tumors showed the ex-
pected decrease in AKT, 4EBP1, and S6 phosphorylation, and
it is important to note that Bcl-2, Bcl-xL, and IGF1Rb were upre-
gulated in response to treatment (Figure 7C). These results
provide evidence that PI3K/mTOR inhibition in vivo induces
a similar adaptive response as in 3D spheroids and monolayer
culture in vitro and that Bcl-2 family inhibition can significantly
enhance the efficacy PI3K/mTOR inhibition in vivo.
To address whether primary patient samples are sensitive to
combination treatment, we isolated cancer cells from pleural
and peritoneal fluid exudates from two breast cancer patients
and two ovarian cancer patients. These samples were cultured
in reconstituted basement membrane for 8 days followed by
treatment with BEZ235, ABT-263 (BCL2 inhibitor similar to
ABT-737; Ackler et al., 2008), PD168393, and combinations for
48 hr. Single-agent inhibition did not show significant efficacy
in any of the treated patient samples (Figure 7D). The response
to dual inhibition of PI3K/mTOR and EGFR was heterogeneous,
only reaching significance in ovarian sample F44 (Figure 7D).–239, February 14, 2012 ª2012 Elsevier Inc. 233
Figure 6. Analysis of BEZ235-Treated Normal Breast Epithelial Cells and Breast Tumor Cell Lines
(A) RPPA analysis of breast cancer cell line spheroids and MCF10A cell monolayers treated with BEZ235 for 48 hr (red, increased signal upon BEZ235 treatment;
green, decreased signal upon BEZ235 treatment). Samples are normalized against DMSO-treated controls.
(B and C) T-47D, MDA-MB-468, and HCC-1569 breast cancer cells lines (in 6B) and nontransformed immortalized MCF10A breast epithelial cells (in 6C) were
cultured in Matrigel and treated with DMSO, BEZ235, or ABT737 alone or in combination for 48 hr. Cells were imaged by phase contrast, fixed, stained with EtBr
(red) to mark dead cells, and imaged by wide-field phase contrast microscopy. Scale bar, 200 mm.
(D) Immunoblots of MCF-10A cells treated with DMSO or BEZ235 for 48 hr. See also Figure S4.
Cancer Cell
Adaptive Resistance to PI3K/mTOR InhibitionHowever, all four samples showed significant response to dual
treatment of BEZ235 and ABT-263 (Figure 7D). Together, these
preliminary results suggest that further evaluation of this drug
combination in more in vivo models and primary human tumor
samples is warranted.
DISCUSSION
Here, using 3D spheroid cell cultures, we show that matrix-
attached tumor cells are specifically resistant to dual PI3K/234 Cancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc.mTOR inhibition by inducing an adaptive response involving up-
regulation of multiple prosurvival proteins. Induction of the
adaptive response involves increased cap-independent transla-
tion and FOXO mediated transcription. It is interesting that this
response resembles the highly conserved stress response
induced in organisms deprived of nutrients and growth factors
(Gilbert et al., 2007; Jefferson and Kimball, 2003; Marr et al.,
2007; Puig and Tjian, 2005; Villa-Cuesta et al., 2010). In addition,
this work establishes the 3D-based model system, particularly in
combination with a high throughput proteomics approach, as
Figure 7. Dual Inhibition of Bcl-2 and PI3K/mTOR in an In Vivo Xenograft Model and in Primary Patient Samples Causes Decreased Tumor
Growth and Enhanced Cell Death
(A) MCAS and OV2008 cells were injected subcutaneously into female nod/scid mice and, after tumors were palpable, mice were treated every 24 hr with vehicle,
GNE493 (mTOR inhibitor, 7mg/kg), ABT-737 (70mg/kg), or a combination of both. Tumorsweremeasured on indicated days, and the data are reported as the fold
change relative to size of the same tumor on Day 1. The data, represented as the average ± SEM, were derived from experiments in which 72 tumors were
monitored in 43 mice for MCAS and 40 tumors were monitored in 20 mice for OV2008. ***p < 0.001; **p < 0.005.
(B) Tumor sections from MCAS xenografts were stained with H&E and imaged at 43. Representative images of tumors of similar size (300mm3) for each
treatment are shown. Scale bar, 100 mm.
(C) Western blot analysis of vehicle- and GNE493-treatedMCAS tumors. Tumors were harvested 4 hr after the last dosing on Day 7 and probed with the indicated
antibodies. Numbers above each lane indicate tumor numbers.
(D) Tumor cells isolated from peritoneal or pleural fluid exudates were cultured in Matrigel for 8 days and treated with the indicated inhibitors (ABT-263, an
identical Bcl-2 inhibitor to ABT-737). Cell death was quantified by analysis of dead cells (as marked by EtBr) over total cell number (as analyzed by Hoechst stain).
*p < 0.05; **p < 0.01; ***p < 0.005. Red boxes indicate average data distribution, and highest and lowest value are indicated with connected red caps. Single blue
caps indicate SD and connected blue caps indicate ± SEM.
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combinations.
Although treatment of cancer cells in monolayer cultures with
PI3K/mTOR inhibitors suppresses cell proliferation, apoptosis is
not commonly observed. In contrast, these inhibitors are potent
inducers of apoptosis of inner cells within 3D spheroid cultures
that are not attached to matrix, whereas cells in 2D cultures
and the outer cells of tumor spheroids induce a strong survivalCprogram and provide an explanation for the lack of toxicity of
PI3K/mTOR inhibitors in traditional 2D cultures. The enhanced
sensitivity of the inner cells of 3D spheroids to apoptosis infers
that PI3K activity is specifically required for survival of this
population of tumor cells. The inner cells in 3D spheroids lack
exposure to ECM components and likely rely on sustained
PI3K activity for anchorage-independent survival. Indeed, onco-
genic mutant variants of PI3K have been shown to rescue cellsancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc. 235
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2005; Martin et al., 2006; Schafer et al., 2009). These studies,
together with our studies of spheroid cultures, highlight the crit-
ical role of the PI3K pathway in the survival of matrix-deprived
cells and raise the question whether human epithelial tumor cells
may display differential sensitivity to PI3K inhibitors depending
on their differential association with ECM components.
The matrix-attached tumor cells initiate a transcriptional and
translational program in response to PI3K/mTOR inhibition
involving expression of signaling proteins that regulate survival.
Whether the induction of this program by PI3K/mTOR inhibitors
is exclusively due to ECM attachment or is dependent on other
features of the outer cells (e.g., cell-cell adhesion or polarity)
remains to be established. Weaver and coworkers have shown
that a6/b4-integrin-dependent cell polarity controls responses
to apoptotic stimuli via NFkB activation in normal epithelial cells
(Friedland et al., 2007; Weaver et al., 2002); however, polarity
of the outer cells was not required for protection in this study,
and inhibition of NFkB signaling by expression of the NFkB
super-repressor did not induce cell death in OV2008 BEZ235-
treated cells. It has also been shown that b4-integrin signaling
can enhance RTK signaling, invasion, and metastasis through
c-Jun and STAT3 (Guo et al., 2006); however, expression of
dominant-negative c-Jun or downregulation of STAT3 did not
prevent the adaptive response to PI3K/mTOR inhibition in our
system (T.M., unpublished results). While integrins are likely crit-
ical for the induction of the adaptive response, wewere unable to
identify a specific integrin or downstream component that plays
a dominant role in the response, suggesting that this adaptive
response is robust and likely includes several components of
the integrin-signaling pathway.
Inhibition of PI3K pathway has been shown to relieve negative
feedback inhibition of upstream pathways. Recently, two reports
(Chandarlapaty et al., 2011; Garrett et al., 2011) described induc-
tion of expression of RTKs by FOXO transcription factors after
inhibition of HER2 or AKT. We also observed significant enrich-
ment in FOXO transcriptional targets after BEZ235 treatment,
suggesting a role for FOXO transcription factors in the induction
of the adaptive response at the mRNA level. However, our
studies involving amore comprehensive proteomic approach re-
vealed a much broader BEZ235-induced program involving
significant translational regulation. Several lines of evidence
support a role for cap-independent translation in the adaptive
response. First, decreased p-4E-BP1 correlated with upregula-
tion of Bcl-2 and IGF1Rb. Because 4E-BP1 is a potent inhibitor
of cap-dependent translation (Choo et al., 2008; Hsieh et al.,
2010; Thoreen et al., 2009), this evidence, together with the pres-
ence of predicted or validated IRES sequences in many of the
upregulated proteins, raised the possibility that cap-indepen-
dent translation contributes to this program. In addition, using
two reporters, we found that BEZ235 (but not rapamycin, which
does not inhibit 4E-BP1 significantly, or a selective PI3K inhibitor)
caused an increase in IRES-mediated translation and a signifi-
cant decrease in cap-dependent translation, supporting the utili-
zation of cap-independent translation in the context of mTOR
inhibition.
Cells downregulate global translation under stress and rely on
the less efficient cap-independent translation for production
of proteins critical for cell survival (Holcik and Sonenberg,236 Cancer Cell 21, 227–239, February 14, 2012 ª2012 Elsevier Inc.2005; Silvera et al., 2010). Our results suggest that cancer cells
may use a similar program to mediate survival under the stress
of PI3K/mTOR inhibition. PI3K pathway inhibition not only
reduces growth factor signaling but also inhibits nutrient uptake,
mimicking nutrient starvation. It is not surprising that the
adaptive response to PI3K/mTOR inhibition resembles the
highly conserved stress responses observed in lower eukaryots
in response to nutrient deprivation as well as endoplasmic
reticulum, irradiation, or oxidative stress (Fels and Koumenis,
2006; Sengupta et al., 2010; Wek et al., 2006). In Drosophila
melanogaster, nutrient deprivation leads to repression of cap-
dependent translation and dFoxO-mediated induction of insulin
receptor expression. Both dFoxO and insulin receptor can be
translated via IRES-mediated mechanisms and are required for
survival (Marr et al., 2007; Villa-Cuesta et al., 2010). A similar
response to dietary restriction is also observed inCaenorhabditis
elegans (Syntichaki et al., 2007). The adaptive response to
nutrient or amino acid starvation also requires eIF2a phosphory-
lation, which decreases translation initiation generally; however,
some IRES-containing mRNAs are preferentially translated
(Allam and Ali, 2010; Fernandez et al., 2002; Gerlitz et al.,
2002; Terenin et al., 2008). It is interesting that eIF2a phosphor-
ylation also contributes to cell survival upon glucose deficiency
and is associated with increased XIAP and Bcl-xL translation,
both of which have been shown to harbor IRES sequences
(Muaddi et al., 2010). Given that PI3K pathway inhibition
suppresses glucose and amino acid transport and that mTOR
inhibition suppresses cap-dependent translation (Choo et al.,
2008; Hsieh et al., 2010; Thoreen et al., 2009), the evidence
that combined PI3K/mTOR inhibitors elicit responses similar to
those induced by nutrient starvation is not surprising. However,
it has not been appreciated that targeted therapies would elicit
these types of responses and that these would be amenable to
rational therapeutic targeting.
Among the PI3K/mTOR inhibitor upregulated proteins, RTKs
and antiapoptotic Bcl-2 familymemberswere themost attractive
targets for combination therapies, given their known role in cell
survival. It is of interest that tamoxifen- or HER2/EGFR-resistant
tumors display upregulation of several of the same targets, such
as IGF1R, EGFR, and HER2 (Creighton et al., 2008; Massarweh
et al., 2008; Plati et al., 2011; Riggins et al., 2007), and chemore-
sistance in ovarian carcinomas is associated with upregulation
of Bcl-2 and Bcl-xL (Gime´nez-Bonafe´ et al., 2009; Jain and
Meyer-Hermann, 2011; Plati et al., 2011; Walensky, 2006). In
addition, irradiation (Holcik et al., 1999; Holcik et al., 2000) and
hypoxia can both induce the switch to cap-independent transla-
tion (Braunstein et al., 2007), suggesting that upregulation of the
pathways that we observed in this study could represent amech-
anistic explanation of resistance to multiple types of cancer
therapy.
Although further studies are required, our initial in vivo xeno-
graft studies and analysis of breast and ovarian cancer patient
samples suggest that inhibition of both Bcl-2 and PI3K/mTOR
may bemore effective than either alone. Furthermore, the effects
of inhibition of Bcl-2 family members and PI3K/mTOR may be
more general than the combination of PI3K/mTOR and EGFR if
different RTKs are activated in tumor samples. It is interesting
that nontransformed epithelial cells were highly resistant to
combined treatment with BEZ235 and ABT737. We speculate
Cancer Cell
Adaptive Resistance to PI3K/mTOR Inhibitionthat one contributing factor might be the proapoptotic protein
Bim, which is upregulated in the BEZ235-treated tumor cell lines
but not in MCF-10A cells.
The results presented here demonstrate that inhibition of
PI3K/mTOR in matrix-attached cancer cells initiates an evolu-
tionarily conserved cellular stress response, mediated by
FOXO transcription factors and preferential translation of IRES-
containing mRNAs. This response leads to upregulation of
signaling pathways required for cancer cell survival but only in
populations of tumor cells within a specific niche (i.e., matrix-
attached cells). It is possible that this stress response could
contribute to relapse after treatment and possibly to the devel-
opment of resistant tumor cells within matrix-associated niches
in human tumors exposed to PI3K/mTOR inhibitors.EXPERIMENTAL PROCEDURES
Additional experimental procedures are described in detail in the Supple-
mental Experimental Procedures.
Antibodies and Reagents, Cell Culture, Cell Lines, and Virus
Production
These are described in the Supplemental Experimental Procedures.
In Vivo Xenograft Experiments
Onemillion cells (MCAS andOV2008) were injected per flank, subcutaneously,
into 10- to 12-week-old female Nod/Scid mice in a 1:1 mix of PBS and
Matrigel. Once tumors became palpable (250 mm3), generally Day 8 postin-
jection for MCAS and Day 28 for OV2008, drugs were administered daily
intraperitoneally. GNE493 (70mg/kg) was dissolved in 0.5% methylcellulose/
0.2% Tween 80, and ABT-737 was dissolved in 30% propylene glycol/5%
Tween 80/65% D5W (5% dextrose in water). All animal studies were per-
formed according to protocols approved by the Institutional Animal
Care and Use Committee, the Standing Committee on Animals at Harvard
University.
Primary Patient Samples
Primary cells were obtained from patients at Brigham and Women’s Hospital
(BWH) who underwent paracentesis for malignant ascites. The protocol was
approved by the BWH Institutional Review Board (IRB), the Harvard Medical
School Office for Research Subject Protection, and the Partners Human
Research Committee. Consent from patients was obtained as per IRB guide-
lines. The fluid exudate samples were briefly centrifuged, and the cell pellet
was washed with PBS. Red blood cells were lysed with Hybri-Max red blood
cell lysis buffer (Sigma No. 7757), and the tumor cells were washed in PBS
and media and allowed to grow one passage in 2D culture before they were
used for the 3D assays. Media for the primary samples was same as for the
ovarian cell lines.
3D Acinar Morphogenesis Assay and Scoring of 3D Structures
Our previously reported MCF-10A 3D cell culture protocol (Debnath et al.,
2003a) (https://brugge.med.harvard.edu/) was modified in the following way
for 3D culture of ovarian cancer cell lines: Cells were grown in MCBD105:199
media (described in Supplemental Experimental Procedures) supplemented
with 2% inactivated calf serum that was replaced every 4 days. For protein
and mRNA, cells were grown on poly-HEMA-coated plates with 2% matrigel.
The 3D structures were scored according to 3D structure integrity based on
the resemblance to images shown in Figure 3B. Over 200 structures were
scored for each condition.
RPPA Assay
RPPA experiments were performed as previously described (Hennessy et al.,
2010).CACCESSION NUMBERS
The data from the microarrays have been deposited in the GEO database with
accession number GSE28992.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
ccr.2011.12.024.
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